Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Summary

DelveInsight’s, “Transforming Growth Factor Beta (TGFb) Inhibitor - Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Transforming Growth Factor Beta (TGFb) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Transforming Growth Factor Beta (TGFb) Inhibitor: Understanding

Transforming Growth Factor Beta (TGFb) Inhibitor: Overview

Transforming growth factor (TGF)-? is a secreted multifunctional cytokine that signals via plasma membrane TGF-? type I and type II receptors and intercellular SMAD transcriptional effectors. Aberrant inter- and intracellular TGF-? signaling can contribute to cancer progression. In normal cells and early stages of cancer, TGF-? can stimulate epithelial growth arrest and elicit a tumor suppressor function. However, in late stages of cancer, when the cytostatic effects of TGF-? in cancer cells are blocked, TGF-? signaling can act as tumor promoter by its ability to stimulate epithelial-to-mesenchymal transition of cancer cells, by stimulating angiogenesis, and by promoting evasion of immune responses. The inhibition of TGF? signaling pathway has emerged as a viable and promising therapeutic target for developing a cancer treatment.

In the early malignant stage, TGF-? secreted by tumor or stromal cells plays a tumor suppressor role by inducing cell-cycle arrest and promoting apoptosis. TGF-? causes late G1 cycle arrest by regulating the expression of cyclin-dependent kinases (CDK) inhibitors, p21 and c-Myc, to inhibit cell cycle progression. In addition, TGF-? can induce apoptosis by upregulating apoptotic regulators such as Bcl-2-like protein 11 (BIM), BCL-2 interacting killer (BIK), and death associated protein kinase (DAPK). Cancer cells often bypass the TGF-?-induced cytostatic effects and apoptosis by mutating key components of the TGF-? pathway. In pre-malignant cancer progression, the function of TGF-? signaling changes from a tumor suppressor to a tumor promoter. TGF-? is also responsible for regulating stroma cells in the tumor microenvironment (TME).

Transforming growth factor beta (TGF-?) is a multifunctional cytokine that plays a pivotal role in regulating a wide range of biological processes essential for maintaining cellular homeostasis and tissue integrity. These processes include cell proliferation, differentiation, apoptosis, immune modulation, extracellular matrix production, and tissue remodeling. Under normal physiological conditions, TGF-? contributes to wound healing and immune regulation. However, dysregulation of the TGF-? signaling pathway is implicated in the pathogenesis of numerous diseases, making it a highly attractive and versatile therapeutic target. Chronic overexpression or aberrant activation of TGF-? has been observed in several disease states, notably in fibrotic disorders, various cancers, and ophthalmic conditions such as age-related macular degeneration (AMD). In ophthalmology, specific genetic variants that influence the TGF-? pathway have been associated with a heightened risk of developing more severe forms of AMD, indicating that TGF-? may actively contribute to disease onset and progression by promoting chronic inflammation, fibrosis, and angiogenesis within ocular tissues. In oncology, the role of TGF-? is complex and highly context-dependent. In early-stage cancers, it may function as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis. However, as tumors evolve, cancer cells often hijack the TGF-? pathway to promote epithelial-to-mesenchymal transition (EMT), immune evasion, angiogenesis, and metastasis effectively transforming TGF-? into a pro-oncogenic factor.

Beyond direct inhibition of TGF-? ligands or their receptors, alternative approaches aim to selectively modulate specific components of the TGF-? signaling pathway or interfere with downstream signaling mechanisms. These strategies may include targeting intracellular mediators, transcriptional regulators, or other pathway components that contribute to the pro-tumorigenic effects of TGF-? while potentially preserving its physiological functions. Such selective or indirect approaches are being explored to improve the therapeutic window of TGF-? pathway inhibition and reduce the potential toxicity associated with broad blockade of TGF-? signaling.

"Transforming Growth Factor Beta (TGFb) Inhibitor- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Transforming Growth Factor Beta (TGFb) Inhibitor pipeline landscape is provided which includes the disease overview and Transforming Growth Factor Beta (TGFb) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Transforming Growth Factor Beta (TGFb) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Transforming Growth Factor Beta (TGFb) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Transforming Growth Factor Beta (TGFb) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Transforming Growth Factor Beta (TGFb) Inhibitor.

Transforming Growth Factor Beta (TGFb) Inhibitor Emerging Drugs Chapters

This segment of the Transforming Growth Factor Beta (TGFb) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Transforming Growth Factor Beta (TGFb) Inhibitor Emerging Drugs

• Elritercept (HS-20106): Takeda/Hansoh Pharma

Elritercept (HS-20106) is a TGF-? pathway inhibitor and engineered ligand-trap fusion protein, originally developed as KER-050 by Keros Therapeutics and licensed to Hansoh Pharma for development in Greater China, with Takeda involved in its global development. The drug consists of a modified ligand-binding domain of activin receptor type IIA (ActRIIA) fused to the Fc domain of a human antibody. By binding and trapping selected ligands of the TGF-? superfamily, including activin A, elritercept is designed to modulate aberrant signaling involved in ineffective blood-cell production. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Anaemia and Myelofibrosis.

• AdAPT-001: EpicentRx

AdAPT-001 represents a novel investigational immunotherapy leveraging a replicative type 5 adenovirus. This adenovirus is equipped with a TGF-? receptor-immunoglobulin Fc fusion trap designed to neutralize TGF-? isoforms 1 and 3, which are implicated in fibrosis, angiogenesis, hypoxia, and immunosuppression within the tumor microenvironment. By targeting these cytokines, AdAPT-001 aims to enhance tumor sensitivity to checkpoint blockade therapies. The combination of AdAPT-001 with checkpoint inhibitors has not only improved toxicity and adverse event profiles compared to checkpoint inhibitors alone but has also demonstrated no dose-limiting toxicities, serious adverse events related to AdAPT-001, or necessary dose reductions thus far. This suggests a potentially safer and more effective treatment strategy for resistant tumors. Currently, the drug is in Phase II stage of its clinical trial for the treatment of several tumor types including STS, colorectal cancer, breast cancer and hepatocellular carcinoma.

• AK130: Akeso Biopharma

AK130 is a TIGIT/TGF-? bifunctional antibody fusion protein being developed as an immuno-oncology therapy. It consists of an anti-TIGIT monoclonal antibody fused with the extracellular domain of human TGF-? receptor II (TGF-?RII). By simultaneously blocking TIGIT-CD155 signaling and trapping TGF-?, AK130 is designed to relieve immune suppression, enhance the activity of tumor-infiltrating CD8+ T cells and NK cells, and reduce TGF-?-mediated immunosuppressive effects in the tumor microenvironment. Akeso has developed AK130 for the treatment of advanced solid tumors and is evaluating it both as monotherapy and in combination with ivonescimab. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Pancreatic Cancer.

• STP707: Sirnaomics

STP707 is an RNAi-based dual TGF-?1/COX-2 inhibitor being developed for the treatment of solid tumors. It consists of two small interfering RNA (siRNA) molecules targeting TGF-?1 and COX-2 mRNAs, formulated in Sirnaomics’ proprietary histidine-lysine polypeptide (HKP+H) nanoparticle delivery system for intravenous administration. By silencing TGF-?1 and COX-2 gene expression, STP707 is designed to reduce TGF-?1-mediated immunosuppression and COX-2-mediated pro-tumorigenic signaling, thereby enhancing antitumor immune responses and promoting T-cell infiltration into the tumor microenvironment. Sirnaomics is developing STP707 for solid tumors, including liver cancer. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Solid tumors.

Further product details are provided in the report……..

Transforming Growth Factor Beta (TGFb) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Transforming Growth Factor Beta (TGFb) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Transforming Growth Factor Beta (TGFb) Inhibitor

There are approx. 20+ key companies which are developing the therapies Transforming Growth Factor Beta (TGFb) Inhibitor. The companies which have their Transforming Growth Factor Beta (TGFb) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Takeda and others.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Transforming Growth Factor Beta (TGFb) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Transforming Growth Factor Beta (TGFb) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Transforming Growth Factor Beta (TGFb) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transforming Growth Factor Beta (TGFb) Inhibitor drugs.

Transforming Growth Factor Beta (TGFb) Inhibitor Report Insights

• Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Transforming Growth Factor Beta (TGFb) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Transforming Growth Factor Beta (TGFb) Inhibitor drugs?
• How many Transforming Growth Factor Beta (TGFb) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Transforming Growth Factor Beta (TGFb) Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Transforming Growth Factor Beta (TGFb) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Transforming Growth Factor Beta (TGFb) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda
• Hansoh Pharma
• iOnctura
• Sirnaomics
• EpicentRx
• Akeso Biopharma
• Scholar Rock
• Oncotelic Inc.
• MedPacto, Inc.

Key Products

• Elritercept/HS-20106
• IOA-359
• STP707
• AdAPT-001
• AK130
• SRK-181
• OT-101
• STP705
• STP355
• Vactosertib